Transcribed
Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence”
Jun 8, 2026 ·
7m 52s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence”
This automatic transcript is brought to you by
Sounder.AI
This is an automatically generated transcript. Please note that complete accuracy is not guaranteed.
Description
In 2023, the FDA approved escitalopram (Lexapro) for generalized anxiety disorder (GAD) in children aged 7 and older, based largely on one industry-sponsored trial showing a small statistical edge over...
show more
In 2023, the FDA approved escitalopram (Lexapro) for generalized anxiety disorder (GAD) in children aged 7 and older, based largely on one industry-sponsored trial showing a small statistical edge over placebo on the Pediatric Anxiety Rating Scale (PARS). Critics argue the benefits fall below clinically meaningful thresholds while risks—particularly a roughly six-fold increase in treatment-emergent suicidal ideation—raise serious concerns about the risk-benefit balance. This episode explores the trial data, study limitations, broader context of pediatric antidepressant use, and what it means for families and clinicians navigating anxiety treatment options.
show less
Information
| Author | Circle Of Insight Productions |
| Organization | Circle Of Insight Productions |
| Website | - |
| Tags |
Copyright 2026 - Spreaker Inc. an iHeartMedia Company
Comments